Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1Phase 1 1

Status

Completed 3Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Myeloid 1Genitourinary 1

Conditions

Prostate Cancer Patients Undergoing Radical Prostatectomy 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × Infusions, Intravenous × Clear all
NCT07024030 2025-06-17

DGPR1008

The Affiliated Hospital of Qingdao University

Phase 2 Completed
24 enrolled
Genitourinary

Prostate Cancer Patients Undergoing Radical Prostatectomy

NCT03238248 2024-11-04

Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
71 enrolled 13 charts
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT01023958 2017-11-22

Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer

Boehringer Ingelheim

Phase 2 Completed
50 enrolled 29 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡